Baseline characteristics
| Ranibizumab | Aflibercept | p Value | |
| No of eyes | 942 | 942 | |
| Right eyes, n (%) | 480 (47.77) | 500 (53.08) | 0.38 |
| Female, n (%) | 598 (63.48) | 598 (63.48) | 1.00 |
| Mean visual acuity at presentation, ETDRS letters (SD) | 55.01 (15.63) | 54.89 (15.99) | 0.88 |
| Mean year of starting therapy (SD) | 2013.24 (0.59) | 2013.93 (0.50) | 2.2e-16* |
*p-value <0.05.
ETDRS, Early Treatment Diabetic Retinopathy Study.